[1]
Wisniewski K.E.: Down syndrome children often have brain with
maturation delay, retardation of growth, and cortical dysgenesis. Am J
Med Genet 1990; 7: 274–281.
[2]
Holland A.J., Hon J., Huppert F.A. et al.: Population-based study of
the prevalence and presentation of dementia in adults with Down’s
syndrome. British Journal of Psychiatry 1998; 172: 493–498.
[3]
Prasher V.P., Krishnan V.H.R.: Age of onset and duration of dementia in
people with Down syndrome: integration of 98 reported cases in the
literature. International Journal of Geriatric Psychiatry 1993; 8(11): 915–
922.
[4]
Dierssen M., Ramakers G.J.: Dendritic pathology in mental retardation:
from molecular genetics toneurobiology. Genes Brain Behav 2006; 5(2):
48-60.
[5]
Kowalska A.: Amyloid precursor protein gene mutationsresponsible for
early-onset autosomal dominant Alzheimer’s disease. Folia Neuropathol
2003; 41: 35-40.
[6]
Kasuga K., Shimohata T., Nishimura A. et al.: Identification of independent
APP locus duplication in Japanese patients with early-onset Alzheimer
disease. Journal of Neurology, Neurosurgery and Psychiatry 2009;
80(9): 1050–1052.
[7]
A. Rovelet-Lecrux A., Hannequin D., Raux G. et al.: APP locus duplication
causes autosomal dominant early-onset Alzheimer disease with cerebral
amyloid angiopathy. Nature Genetics 2006; 38(1): 24–26.
[8]
Wolvetang E.W., Bradfield O.M., Tymms M. et al.: The chromosome
21 transcription factor ETS2 transactivates the β-APP promoter:
implications for Down syndrome. Biochimica et Biophysica Acta – Gene
Structure and Expression 2003; 1628(2): 105–110.
[9]
Durackova Z., Garaiova I., Muchova J. et al.: Metabolism of glutathione
at the persons with Down syndrome. Free Radic Biol Med 1999; 27: 120.
[10]
Sobaniec W.: Lipid peroxidation in experimental and clinical epilepsy
and the effects of sodium valproate and vitamin E on these processes.
Neurosciences 1992; 18: 123-130.
[11]
Sobaniec W., Kułak W., Sobaniec H. et al.: Effects of clobazam and
vitamin E on the lipid peroxidation in the rat brain after electroconvulsive
shock. Ann Acad Med Bial 1999; 44: 134-140.
[12]
Warner B.B., Wispe J.R.: Free radical-mediated diseases in pediatrics.
Semin Perinatol 1992; 16(1): 47-57.
[13]
Artemowicz B., Sobaniec W.: Investigation of lipid peroxidation
and antioxidant enzymes activity in the serum of epileptic children.
Epileptologia 2001; 9(2): 167-178.
[14]
Kuloglu M., Ustundag M., Atmaca M. et al.: Lipid peroxidation and
antioxidant enzyme levels in patients with schizophrenia and bipolar
disorder. Cell Biochem Funct 2002; 20(2): 171-175.
[15]
Michiels C., Raes M., Toussaint O. et al.: Importance of Se glutathione
peroxidase, catalase, and Cu/Zn SOD for cell survival against oxidative
stress. Free Radic Biol Med 1994; 17(3): 235-248.
[16]
Vento M., Asensi M., Sastre J. et al.: Oxidative stress in asphyxiated
term infants resuscitated with 100% oxygen. J Pediat 2003; 142(3): 240-
246.
[17]
Murphy M., Insoft R.M., Pike-Nobile L. et al.: A hypothesis to explain the
immune defects in Down syndrome. Prog Clin Biol Res 1995; 393: 147-
167.
[18]
Blasko I., Ransmayr G., Veerhius R. et al.: Does INF-γ play a role in
neurodegeneration? J Neuroimmunol 2001; 116: 1-4.
[19]
Weisgraber K.H., Roses A.D., Strittmatter W.J.: The role of apolipoprotein
E in the nervous system. Curr Opin Lipidol 1994; 5: 110-116.
[20]
Park E., Alberti J.P., Mehta P. et al.: Partial impairment of immune
functions in peripheral blood leukocytes from aged men with Down’s
syndrome. Clin Immunol 2000; 95: 62-69.
[21]
Castaldo V.: Down’s syndrome: a study of sleep patterns related to level
of mental retardation. Am J Ment 1969; 74: 187-90.
[22]
Fishbein W.: Disruptive effects of rapid eye movement sleep deprivation
on long term memory. Physiol Behav 1971; 6: 279-282.
[23]
McGrath M.J., Cohen D.B.: REM sleep facilitation of adaptive waking
behaviour: a review of literature. Psychol Bull 1978; 85: 24-57.
[24]
Śmigielska-Kuzia J., Sobaniec W., Kułak W.: Ocena skojarzonego
leczenia karbamazepiną i piracetamem dzieci z padaczką. Epileptologia
(in polish) 2002; 10: 145-157.
[25]
Śmigielska-Kuzia J., Sobaniec W.: Ocena skuteczności piracetamu w
porównaniu z flunaryzyną w leczeniu migreny i napięciowych bólów
głowy u dzieci. Neurol Dziec (in polish) 2002; 11: 45-58.
[26]
Petit D., Lorrain D., Gauthier S. et al.: Regional spectral analysis of the
REM sleep EEG in mild to moderate Alzheimer’s disease. Neurobiol
Aging 1993; 14: 141-145.
[27]
Majuri S., Kaski M., Hartikainen P.: Age-related cognitive decline and
electroencephalogram slowing in Down’s syndrome as a model of
Alzheimer’s disease. Neuroscience 1993; 53: 57-63.
[28]
Achermann P., Borbely A.A.: Low-frequency (1 Hz) oscillations in the
human sleep electroencephalogram. Neuroscience 1997; 81: 213-222.
[29]
Partanen J., Soininen H., Kononen M.: EEG reactivity correlates with
neuropsychological test scores in Down’s syndrome. Acta Neurol Scand
1996; 94: 242-246.
[30]
Murata T., Koshino Y., Omori M. et al.: Quantitative EEG study on
premature aging in adult Down’s syndrome. Biol Psychiatr 1994; 35:
422-425.
[31]
Ono Y., Yoshida H., Momotani Y. et al.: Agerelated changes in occipital
alpha rhythm of adults with Down syndrome. Jpn J Psychiatry Neurol
1992; 46: 659-664.
[32]
Goldberg-Stern H., Strawsburg R.H., Patterson B. et al.: Seizure
frequency and characteristics in children with Down syndrome. Brain
Dev 2001; 23: 375-378.
[33]
Stafstrom C.E., Patxot D.F., Gilmore H.E. et al.: Seizures in children with
Down syndrome: etiology, characteristics and outcome. Dev Med Child
Neurol 1991; 33: 191-200.
[34]
Stafstrom C.E.: Epilepsy in Down syndrome: clinical aspects and
possible mechanisms. Am J Ment Retard 1993; 98: 12-26.
[35]
Kułak W., Sobaniec W., Kubas B. et al.: Proton magnetic resonance
spectroscopy in children with spastic diplegia. Neurosci Lett 2004; 636:
62-64.
[36]
Walecki J., Tarasow E., Kubas B. et al.: Hydrogen-1 MR spectroscopy of
the peritumoral zone in patients with cerebral glioma: assessment of the
value of the method. Acad Radiol 2003; 10: 145-153.
[37]
Murata T., Koshino Y., Omori M. et al.: In vivo proton magnetic resonance
spectroscopy study on premature aging in adult Down’s syndrome. Biol
Psychiatry 1993; 1: 290-297.
[38]
Berry G.T., Wang Z.J., Dreha S.F. et al.: In vivo brain myo-inositol levels
in children with Down syndrome. J Pediatr 1999; 135: 94-97.
[39]
Watson C., Andermann F., Gloor P. et al.: Anatomic basis of amygdaloid
and hippocampal volume measurement by magnetic resonance imaging.
Neurology 1992; 42: 1743-1750.
[40]
Frangou S., Aylward E., Warren A. et al.: Small Planum Temporale
Volume in Down’s Syndrome: A Volumetric MRI Study. Am J Psychiatry
1997; 154: 1424–1429.
[41]
Haier R.J., Head K., Head E. et al.: Neuroimaging of individuals
with Down’s syndrome at-risk for dementia: Evidence for possible
compensatory events. Neuroimage 2008; 39(3): 1324-1332.
[42]
Coyle J.T., Oster-Granite M.L., Gearhart J.D.: The neurobiologic
consequences of Down syndrome. Brain Res Bull 1986; 16: 773–787.
[43]
Brun A., Englund E.: Regional pattern of degeneration in Alzheimer’s
disease: neuronal loss and histopathological grading. Histopathology
1981; 5: 549–564.
[44]
Bhatic S., Bookheimer S.Y., Gillard W.D. et al.: Measurement of whole
temporal lobe and hippocampus for MR volumetry: Normative data.
Neurology 1993; 43: 2006.
[45]
Pearlson G.D., Breiter S.N., Aylward E.H. et al.: MRI brain changes in
subjects with Down syndrome with and without dementia. Dev Med
Child Neurol 1998; 40(5): 326-334.
[46]
Pinter J., Joseph D., Schmitt E., et al.: Neuroanatomy of Down’s
Syndrome: A High-Resolution MRI Study. Am J Psychiatry 2001; 158:
1659–1665.
[47]
Jernigan T.L., Bellugi U., Sowell E. et al.: Cerebral morphologic
distinctions between Williams and Down syndromes. Arch Neurol 1993;
50: 186-191.
[48]
Śmigielska-Kuzia J., Sobaniec W., Kułak W. et al.: Antioxidant enzymes
and lipid peroxides in children with Down syndrome. Journal of Pediatric
Neurology 2007; 5: 117-120.
[49]
Jovanovic S.V., Clements D.: Biomarkers of oxidative stress are
significantly elevated in Down syndrome. Free Radic Biol Med 1998; 25:
1044–1048.
[50]
Kedziora, J., Bartosz G.: Down syndrome a pathology involving the lack
of balance of reactive oxygen species. Free Rad Biol Med 1988; 4: 317-
330.
[51]
Cholewa M., Śmigielska-Kuzia J., Sobaniec W. et al.: Ocena aktywności
antyoksydacyjnej w erytrocytach u pacjentów z zespołem Downa.
Neurol Dziec In Press.
[52]
Śmigielska-Kuzia J., Boćkowski L., Sobaniec W., et al.: Anti-inflammatory
plasma cytokines in children and adolescents with Down syndrome.
Folia Histochemica et Cytobiologica 2010; 48(4): 667-670.
[53]
Jakubiuk-Tomaszuk A., Śmigielska-Kuzia J., Wysocka J. et al.: Ocena
subpopulacji limfocytów T CD3+, CD4+ i CD8+ we krwi obwodowej
metodą cytometrii przepływowej u dzieci z zespołem Downa. The
assessment of T lymphocyte subpopulations CD3+, CD4+ and
CD8+ on peripheral blood in children with Down syndrome using flow
cytometric method. In Press.
[54]
Śmigielska-Kuzia J., Sobaniec W., Kułak W. et al.: Quantitative EEG
analysis of REM sleep in children with Down syndrome. Adv Med Sci
2005; 50: 20-22.
[55]
Śmigielska-Kuzia J., Sobaniec W., Kułak W. et al.: Clinical and EEG
features of epilepsy in children and adolescents in Down syndrome. J.
Child. Neurol. 2009; 24: 416-420.
[56]
Śmigielska-Kuzia J., Sobaniec W.: Brain metabolic profile obtained by
proton magnetic resonance spectroscopy HMRS in children with Down
syndrome. Adv Med Sci 2007; 52: 183-187.
[57]
Śmigielska-Kuzia J., Boćkowski L., Sobaniec W. et al.: Amino acid
metabolic processes in the temporal lobes assessed by proton magnetic
resonance spectroscopy (1H MRS) in children with Down syndrome.
Pharmacological Reports 2010; 62: 1070-1077.
[58]
Śmigielska-Kuzia J., Boćkowski L., Sobaniec W. et al.: A volumetric MRI
study of brain structures in children with Down syndrome. Neurologia i
Neurochirurgia Polska. In Press
Scholar Google
PubMed